Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6404075 | 0.84 | PTPRC (0.41) | PTPRCALDH1A1CYP1A2CYP2C9TNF | |
| SCHEMBL13765222 | 0.82 | PTPRC (0.40) | PTPRCALDH1A1TNFMAPTKMT2A | |
| SCHEMBL15991785 | 0.79 | TNF (0.43) | ALDH1A1TNFGAAMEN1KMT2A | |
| SCHEMBL14854420 | 0.79 | TNF (0.43) | ALDH1A1TNFGAAMEN1KMT2A | |
| SCHEMBL29355696 | 0.79 | ALDH1A1 (0.46) | ALDH1A1CYP1A2CYP2C9TNFMAPT | |
| SCHEMBL24307918 | 0.78 | PLA2G1B (0.39) | PTPRCALDH1A1CYP1A2CYP2C9TNF | |
| SCHEMBL9594137 | 0.78 | ALDH1A1 (0.40) | PTPRCALDH1A1CYP1A2CYP2C9TNF | |
| SCHEMBL18414185 | 0.78 | ALDH1A1 (0.55) | PTPRCALDH1A1GAAKMT2ADNMT1 | |
| SCHEMBL13765053 | 0.78 | ALDH1A1 (0.45) | ALDH1A1CYP1A2CYP2C9MAPTGAA | |
| SCHEMBL13790158 | 0.77 | MEN1 (0.48) | ALDH1A1MAPTGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9610263-B2 | Method of modulating membrane potential of a cell | VERSITECH LIMITED (CN) | 2017-04-04 | — | — | US | disclosed |
| US-9610263-B2 | Method of modulating membrane potential of a cell | VERSITECH LIMITED (CN) | 2017-04-04 | — | — | US | disclosed |
| EP-2231137-B1 | METHOD OF MODULATING MEMBRANE POTENTIAL OF A CELL | VERSITECH LTD (CN) | 2017-01-25 | — | — | EP | disclosed |
| WO-2009089680-A1 | METHOD OF MODULATING MEMBRANE POTENTIAL OF A CELL | YANG DAN (CN) | 2009-07-23 | — | — | WO | disclosed |
| US-20090163595-A1 | Method of Modulating Membrane Potential of a Cell | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2009-06-25 | — | — | US | disclosed |
| US-20090163595-A1 | Method of Modulating Membrane Potential of a Cell | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163595-A1 | Method of Modulating Membrane Potential of a Cell | VDAC1, ATP2A3, ATP2A2 | PTPRC 1142/4885ALDH1A1 3766/4885CYP1A2 4810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.